MovDisordV3, PascalFrancis, Corpus, bibRecord, 000B21

Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations

Identifieur interne : 000B21 ( PascalFrancis/Corpus ); précédent : 000B20; suivant : 000B22

Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations

Auteurs : Bonnie P. Hersh ; Nancy L. Earl ; Robert A. Hauser ; Mark Stacy

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0288331

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Traitement, Ropinirole, Libération, Homme, Fluctuation, Echelle d'évaluation.

English descriptors

KwdEn :
- Evaluation scale, Fluctuations, Human, Nervous system diseases, Parkinson disease, Release, Ropinirole, Treatment.

Abstract

We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations`
A11	`01`	`1`		`@1 HERSH (Bonnie P.)`
A11	`02`	`1`		`@1 EARL (Nancy L.)`
A11	`03`	`1`		`@1 HAUSER (Robert A.)`
A11	`04`	`1`		`@1 STACY (Mark)`
A14	`01`			`@1 Department of Neurology, Harvard Vanguard Medical Associates @2 Boston Massachusetts @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Clinical Neurosciences, GlaxoSmithKline @2 Research Triangle Park, North Carolina @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, University, of South Florida @2 Tampa, Florida @3 USA @Z 3 aut.`
A14	`04`			`@1 Division of Neurology, Department of Medicine, Duke University @2 Durham, North Carolina @3 USA @Z 4 aut.`
A20				`@1 927-931`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193040220170`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 10 ref.`
A47	`01`	`1`		`@0 10-0288331`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`04`	`X`	`FRE`	`@0 Ropinirole @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Ropinirole @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Ropinirol @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Libération @5 11`
C03	`05`	`X`	`ENG`	`@0 Release @5 11`
C03	`05`	`X`	`SPA`	`@0 Liberación @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Fluctuation @5 13`
C03	`07`	`X`	`ENG`	`@0 Fluctuations @5 13`
C03	`07`	`X`	`SPA`	`@0 Fluctuación @5 13`
C03	`08`	`X`	`FRE`	`@0 Echelle d'évaluation @5 14`
C03	`08`	`X`	`ENG`	`@0 Evaluation scale @5 14`
C03	`08`	`X`	`SPA`	`@0 Escala evaluación @5 14`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 186`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0288331 INIST
ET :	Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
AU :	HERSH (Bonnie P.); EARL (Nancy L.); HAUSER (Robert A.); STACY (Mark)
AF :	Department of Neurology, Harvard Vanguard Medical Associates/Boston Massachusetts/Etats-Unis (1 aut.); Department of Clinical Neurosciences, GlaxoSmithKline/Research Triangle Park, North Carolina/Etats-Unis (2 aut.); Department of Neurology, University, of South Florida/Tampa, Florida/Etats-Unis (3 aut.); Division of Neurology, Department of Medicine, Duke University/Durham, North Carolina/Etats-Unis (4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 927-931; Bibl. 10 ref.
LA :	Anglais
EA :	We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Traitement; Ropinirole; Libération; Homme; Fluctuation; Echelle d'évaluation
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Treatment; Ropinirole; Release; Human; Fluctuations; Evaluation scale
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Tratamiento; Ropinirol; Liberación; Hombre; Fluctuación; Escala evaluación
LO :	INIST-20953.354000193040220170
ID :	10-0288331

Links to Exploration step

Pascal:10-0288331

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288331</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288331 INIST</idno>
<idno type="RBID">Pascal:10-0288331</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation scale</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Release</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
<term>Ropinirole</term>
<term>Libération</term>
<term>Homme</term>
<term>Fluctuation</term>
<term>Echelle d'évaluation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HERSH (Bonnie P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>EARL (Nancy L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>STACY (Mark)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>927-931</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193040220170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>10 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0288331</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Libération</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Release</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Liberación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Fluctuation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Fluctuations</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Fluctuación</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Echelle d'évaluation</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Evaluation scale</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Escala evaluación</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>186</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0288331 INIST</NO>
<ET>Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</ET>
<AU>HERSH (Bonnie P.); EARL (Nancy L.); HAUSER (Robert A.); STACY (Mark)</AU>
<AF>Department of Neurology, Harvard Vanguard Medical Associates/Boston Massachusetts/Etats-Unis (1 aut.); Department of Clinical Neurosciences, GlaxoSmithKline/Research Triangle Park, North Carolina/Etats-Unis (2 aut.); Department of Neurology, University, of South Florida/Tampa, Florida/Etats-Unis (3 aut.); Division of Neurology, Department of Medicine, Duke University/Durham, North Carolina/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 927-931; Bibl. 10 ref.</SO>
<LA>Anglais</LA>
<EA>We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Traitement; Ropinirole; Libération; Homme; Fluctuation; Echelle d'évaluation</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Treatment; Ropinirole; Release; Human; Fluctuations; Evaluation scale</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Tratamiento; Ropinirol; Liberación; Hombre; Fluctuación; Escala evaluación</SD>
<LO>INIST-20953.354000193040220170</LO>
<ID>10-0288331</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B21 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B21 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0288331
   |texte=   Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations

Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri